Last Price$30.6(0.4%)
Market Cap$1,741.3M
Last Earnings date
Jun'24
Q2 2024
($0.36)
18.2% beat
$0.0
100.0% miss
Next quarter EPS Estimate
($0.37)
48.0%YoY
JANX Earnings and Expectations
Revenue
Crunching data... Almost there!
JANX EPS (Earnings Per Share)
Crunching data... Almost there!
JANX Historical Revenue & EPS and Expectations
1Y
3Y
5Y
10Y
Revenue
EPS
JANX Earnings History
| Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue actual | $0.0 | $0.0 | $0.0 | $0.0 | $380.0K | $482.0K | $1,159.0K | $1,616.0K | $1,589.0K | $2,365.0K | $1,813.0K | $2,845.0K | $2,048.0K | $1,057.0K | $2,517.0K | $2,461.0K | $1,252.0K | $8,897.0K | $439.0K | $0.0 |
| Revenue estimate | N/A | N/A | N/A | N/A | N/A | $133.3K | $133.3K | $433.3K | $810.4K | $650.0K | $742.6K | $805.5K | $672.4K | $875.0K | $845.5K | $750.0K | $878.6K | $772.0K | $1,495.2K | $1,062.8K |
| Revenue surprise | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 261.5% | 769.3% | 272.9% | 96.1% | 263.8% | 144.1% | 253.2% | 204.6% | 20.8% | 197.7% | 228.1% | 42.5% | 1,052.5% | 70.6% | 100.0% |
| EPS actual | ($0.11) | ($0.20) | ($0.10) | ($0.13) | ($0.06) | ($0.62) | ($0.26) | ($0.33) | ($0.32) | ($0.40) | ($0.34) | ($0.39) | ($0.42) | ($0.42) | ($0.25) | ($0.25) | ($0.30) | ($0.11) | ($0.51) | ($0.36) |
| EPS estimate | N/A | N/A | N/A | N/A | N/A | ($0.14) | ($0.18) | ($0.27) | ($0.32) | ($0.32) | ($0.47) | ($0.48) | ($0.49) | ($0.50) | ($0.47) | ($0.42) | ($0.33) | ($0.31) | ($0.33) | ($0.44) |
| EPS surprise | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 342.9% | 47.2% | 22.2% | 0.0% | 26.3% | 27.3% | 18.9% | 13.6% | 16.3% | 46.8% | 39.8% | 9.4% | 64.6% | 55.8% | 18.2% |
Overview of financial statements
Income statement
Balance sheet
Cash Flow statement
Operating
expenses
$29.0M 56.0% YoY
Other: $20.2M
Competing with JANX Earnings
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Revenue | EPS | Last quarter Revenue growth | Last quarter EPS growth | Last quarter Revenue surprise | Last quarter EPS surprise | Next quarter Revenue growth | Next quarter EPS growth | Last 10 Earnings (how many miss vs beat) | 1Y Fwd Revenue growth | 1Y Fwd EPS growth |
$1,741.3M | $10.6M | ($1.28) | (100.0%) | 44.0% | Miss by 100.0% | Miss by 18.2% | 0.0% | 11.9% | Beats: 8 Misses: 2 | 52.1% | 7.5% | |
$388.2B | DKK 290.4B | DKK 22.67 | 30.1% | 28.9% | Beat by 7.9% | Beat by 5.9% | (6.5%) | 0.4% | Beats: 5 Misses: 5 | 20.0% | 23.2% | |
$125.7B | $11.0B | ($2.06) | 15.7% | (5.6%) | Beat by 4.5% | Miss by 11.1% | (3.9%) | 23.5% | Beats: 8 Misses: 2 | 6.8% | (988.1%) | |
$76.1B | $14.2B | $40.88 | 10.3% | (21.6%) | Beat by 0.8% | Miss by 23.9% | (7.6%) | 23.6% | Beats: 7 Misses: 3 | 3.4% | 9.5% | |
$35.7B | $2,258.9M | ($1.77) | 73.8% | N/A | Beat by 40.1% | Miss by 281.3% | 23.0% | 0.7% | Beats: 8 Misses: 2 | 76.9% | (142.5%) | |
$31.4B | $2,248.2M | ($2.17) | 34.9% | (40.9%) | Beat by 1.6% | Beat by 27.8% | (7.3%) | 14.3% | Beats: 7 Misses: 3 | 16.9% | (55.3%) | |
$26.1B | €3,040.1M | (€1.96) | 39.0% | 20.3% | Beat by 761.0% | Miss by 141.1% | (10.3%) | (51.6%) | Beats: 5 Misses: 5 | (28.2%) | (182.9%) | |
$14.1B | $2,877.4M | $26.45 | 19.7% | 45.9% | Miss by 0.5% | Beat by 2.4% | 3.0% | 6.7% | Beats: 5 Misses: 5 | 10.7% | 9.9% | |
$13.7B | $3,229.0M | ($9.29) | (65.7%) | N/A | Miss by 0.7% | Beat by 6.8% | (81.0%) | (0.1%) | Beats: 9 Misses: 1 | (16.2%) | (3.3%) | |
$12.8B | $0.0 | ($0.31) | (100.0%) | 62.6% | undefinedN/A | undefinedN/A | 0.0% | (24.5%) | Beats: Misses: | N/A | 6.8% |
FAQ
1. When was Janux Therapeutics, Inc.'s last earnings date?
Janux Therapeutics, Inc.'s last earnings date was Jun'24 (Q2 2024).
2. What is Janux Therapeutics, Inc.'s EPS, and was there a surprise?
Janux Therapeutics, Inc.'s EPS was ($0.36), with a 18.2% beat.
3. What is Janux Therapeutics, Inc.'s revenue, and was there a surprise?
Janux Therapeutics, Inc.'s revenue was $0.0, with a 100.0% miss.
4. What is Janux Therapeutics, Inc.'s next quarter EPS estimate?
Janux Therapeutics, Inc.'s next quarter EPS estimate is ($0.37), with an expected 48.0% YoY growth.